C Allgulander

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi Prevention of relapse in generalized anxiety disorder by escitalopram treatment
    Christer Allgulander
    Department of Clinical Neuroscience, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Int J Neuropsychopharmacol 9:495-505. 2006
  2. ncbi Victims of criminal homicide in Sweden: a matched case-control study of health and social risk factors among all 1,739 cases during 1978-1994
    C Allgulander
    Neurotec, Division for Psychiatry, Karolinska Institutet, Stockholm, Sweden
    Am J Psychiatry 157:244-7. 2000
  3. ncbi Efficacy of sertraline in a 12-week trial for generalized anxiety disorder
    Christer Allgulander
    Karolinska Institutet, Neurotec Department, Section of Psychiatry at Huddinge, University Hospital, 141 86 Huddinge, Sweden
    Am J Psychiatry 161:1642-9. 2004
  4. ncbi Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine
    Christer Allgulander
    Karolinska Institutet, The Neurotec Department, Section of Psychiatry, Stockholm, Sweden
    Hum Psychopharmacol 19:387-96. 2004
  5. ncbi Long-term treatment strategies in anxiety disorders
    Christer Allgulander
    Karolinska Institute, Neurotec Department, Huddinge University Hospital, Stockholm
    Psychopharmacol Bull 36:79-92. 2002
  6. ncbi Coping with somatic comorbidities: striving for complete recovery
    Christer Allgulander
    Karolinska Institute, Neurotec Department, Huddinge University Hospital, Stockholm
    Psychopharmacol Bull 36:103-11. 2002
  7. ncbi [A nationwide study in primary health care: One out of four patients suffers from anxiety and depression]
    Christer Allgulander
    Karolinska Institutet, NEUROTEC Institutionen, Sektionen för psykiatri, Huddinge Universitetssjukhus
    Lakartidningen 100:832-8. 2003
  8. ncbi Generalized anxiety disorder: raising the expectations of treatment
    Christer Allgulander
    Karolinska Institute, Neurotec Department, Huddinge University Hospital, Stockholm
    Psychopharmacol Bull 36:68-78. 2002
  9. ncbi HIV infection and psychiatric illness
    B Owe-Larsson
    Karolinska Institutet, Department of Clinical Neuroscience, Section of Psychiatry at Karolinska University Hospital Huddinge, Stockholm, Sweden
    Afr J Psychiatry (Johannesbg) 12:115-28. 2009
  10. ncbi Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study
    C Allgulander
    Neurotec/Psychiatry, Huddinge University Hospital, Huddinge, Sweden
    Br J Psychiatry 179:15-22. 2001

Detail Information

Publications28

  1. ncbi Prevention of relapse in generalized anxiety disorder by escitalopram treatment
    Christer Allgulander
    Department of Clinical Neuroscience, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Int J Neuropsychopharmacol 9:495-505. 2006
    ..Escitalopram 20 mg/d significantly reduced the risk of relapse and was well tolerated in patients with GAD...
  2. ncbi Victims of criminal homicide in Sweden: a matched case-control study of health and social risk factors among all 1,739 cases during 1978-1994
    C Allgulander
    Neurotec, Division for Psychiatry, Karolinska Institutet, Stockholm, Sweden
    Am J Psychiatry 157:244-7. 2000
    ..This study was undertaken to determine health and social factors contributing to the risk of being murdered in the Swedish, predominantly Caucasian population...
  3. ncbi Efficacy of sertraline in a 12-week trial for generalized anxiety disorder
    Christer Allgulander
    Karolinska Institutet, Neurotec Department, Section of Psychiatry at Huddinge, University Hospital, 141 86 Huddinge, Sweden
    Am J Psychiatry 161:1642-9. 2004
    ..Sertraline's efficacy and tolerability in treating generalized anxiety disorder were evaluated...
  4. ncbi Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine
    Christer Allgulander
    Karolinska Institutet, The Neurotec Department, Section of Psychiatry, Stockholm, Sweden
    Hum Psychopharmacol 19:387-96. 2004
    ..Both active treatments were generally well tolerated and were associated with a similar incidence of adverse events. This study shows that venlafaxine ER is an effective, safe and well-tolerated drug treatment for SAD...
  5. ncbi Long-term treatment strategies in anxiety disorders
    Christer Allgulander
    Karolinska Institute, Neurotec Department, Huddinge University Hospital, Stockholm
    Psychopharmacol Bull 36:79-92. 2002
    ....
  6. ncbi Coping with somatic comorbidities: striving for complete recovery
    Christer Allgulander
    Karolinska Institute, Neurotec Department, Huddinge University Hospital, Stockholm
    Psychopharmacol Bull 36:103-11. 2002
    ..The results encourage further controlled studies...
  7. ncbi [A nationwide study in primary health care: One out of four patients suffers from anxiety and depression]
    Christer Allgulander
    Karolinska Institutet, NEUROTEC Institutionen, Sektionen för psykiatri, Huddinge Universitetssjukhus
    Lakartidningen 100:832-8. 2003
    ..Doctors were confident in diagnosing and treating them. Five key questions can be used in primary care to screen for these common psychiatric conditions...
  8. ncbi Generalized anxiety disorder: raising the expectations of treatment
    Christer Allgulander
    Karolinska Institute, Neurotec Department, Huddinge University Hospital, Stockholm
    Psychopharmacol Bull 36:68-78. 2002
    ..Many patients treated with venlafaxine XR achieve and sustain remission from the symptoms of GAD, which is the goal of treatment...
  9. ncbi HIV infection and psychiatric illness
    B Owe-Larsson
    Karolinska Institutet, Department of Clinical Neuroscience, Section of Psychiatry at Karolinska University Hospital Huddinge, Stockholm, Sweden
    Afr J Psychiatry (Johannesbg) 12:115-28. 2009
    ..To review the clinical features and current knowledge on the treatment of psychiatric symptoms and disorders in patients with human immunodeficiency virus (HIV) infection...
  10. ncbi Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study
    C Allgulander
    Neurotec/Psychiatry, Huddinge University Hospital, Huddinge, Sweden
    Br J Psychiatry 179:15-22. 2001
    ..The discontinuation rate did not differ significantly among the treatment groups. CONCLUSIONS: Venlafaxine ER is an effective and safe treatment for GAD for up to 6 months...
  11. ncbi A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder
    C Allgulander
    Department of Clinical Neuroscience, Section of Psychiatry, Karolinska Institutet, Stockholm, Sweden
    J Psychopharmacol 22:417-25. 2008
    ..4%). Duloxetine 60-120 mg/day met all statistical and clinical criteria for non-inferiority and exhibited a similar tolerability profile compared with venlafaxine XR 75-225 mg/day for the treatment of adults with GAD...
  12. ncbi Health-related quality of life (HRQOL) among patients with Generalised Anxiety Disorder: evaluation conducted alongside an escitalopram relapse prevention trial
    C Allgulander
    Karolinska Institutet, Stockholm, Sweden
    Curr Med Res Opin 23:2543-9. 2007
    ..Improving health-related quality of life (HRQoL) should be a treatment goal for patients with Generalised Anxiety Disorder (GAD)...
  13. ncbi A prospective study of 86 new patients with social anxiety disorder
    C Allgulander
    Neurotec/Psychiatry, Karolinska Institutet, Stockholm, Sweden
    Acta Psychiatr Scand 103:447-52. 2001
    ..CONCLUSION: Due to their condition, some subjects with social anxiety refrain from effective treatments. The efficacy of serotonergic medication was maintained and augmented after a mean period of 32 months...
  14. ncbi Risk of suicide by psychiatric diagnosis in Stockholm County. A longitudinal study of 80,970 psychiatric inpatients
    C Allgulander
    Department of Psychiatry, Huddinge University Hospital, Stockholm, Sweden
    Eur Arch Psychiatry Clin Neurosci 241:323-6. 1992
    ..Further studies of confounders are needed, such as the reasons for being admitted to inpatient care, and the impact of somatic and psychiatric comorbidity...
  15. ncbi Psychiatric symptoms and disorders in HIV infected mine workers in South Africa. A retrospective descriptive study of acute first admissions
    L Säll
    Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden
    Afr J Psychiatry (Johannesbg) 12:206-12. 2009
    ..We describe the onset of psychiatric symptoms and signs in a group of untreated, HIV infected male mine workers first admitted for psychiatric treatment at the Rand Mutual Hospital in Johannesburg...
  16. ncbi [Do you treat patients with Seroxat?]
    Christer Allgulander
    Lakartidningen 100:2398. 2003
  17. ncbi WCA recommendations for the long-term treatment of panic disorder
    Mark H Pollack
    Division of Psychiatry, Huddinge University Hospital, Stockholm, Sweden
    CNS Spectr 8:17-30. 2003
    ..Long-term efficacy and ease of use are important considerations in treatment selection, as maintenance treatment is recommended for at least 12-24 months, and in some cases, indefinitely...
  18. ncbi Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies
    Jonathan Davidson
    Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA
    Hum Psychopharmacol 23:519-26. 2008
    ..To assess the efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder (GAD)...
  19. ncbi WCA recommendations for the long-term treatment of social phobia
    Michael Van Ameringen
    Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada
    CNS Spectr 8:40-52. 2003
    ..In light of the chronicity and disability associated with social phobia, as well as the high relapse rate after short-term therapy, it is recommended that effective treatment be continued for at least 12 months...
  20. ncbi Gender differences in clinical presentation and response to sertraline treatment of generalized anxiety disorder
    Meir Steiner
    McMaster University, Department of Psychiatry and Behavioural Neurosciences, Women s Health Concerns Clinic, St Joseph s Hospital, Hamilton, Ontario, Canada
    Hum Psychopharmacol 20:3-13. 2005
    ..To evaluate gender differences in the clinical presentation of generalized anxiety disorder (GAD) and response to sertraline treatment...
  21. ncbi Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials
    Christer Allgulander
    Karolinska Institutet, Stockholm, Sweden
    Curr Med Res Opin 23:1245-52. 2007
    ..A pooled dataset from all completed trials is provided here to show the most likely clinical outcomes associated with duloxetine treatment for GAD...
  22. ncbi WCA recommendations for the long-term treatment of generalized anxiety disorder
    Christer Allgulander
    Department of Psychiatry, Harvard University School of Medicine, Boston, Massachusetts, USA
    CNS Spectr 8:53-61. 2003
    ..Treatment gains after a 12-week course of CBT may be maintained for up to 1 year. Currently, no guidelines exist for the long-term treatment of GAD...
  23. ncbi Prevalence of generalized anxiety disorder in general practice in Denmark, Finland, Norway, and Sweden
    Povl Munk-Jørgensen
    Unit for Psychiatric Research, Aalborg Psychiatric Hospital, Aarhus University Hospital, Mølleparkvej 10, Aalborg, Denmark DK 9000
    Psychiatr Serv 57:1738-44. 2006
    ..This study assessed the prevalence rate of generalized anxiety disorder among patients of general practitioners in Denmark, Finland, Norway, and Sweden and determined whether general practitioners recognize the condition and its correlates...
  24. ncbi Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder
    Mikael Landen
    Department of Clinical Neuroscience, Section of Psychiatry St Göran, Karolinska Institutet, Stockholm, Sweden
    Neuropsychopharmacology 32:153-61. 2007
    ..Symptoms such as irritability, affect lability, and mood swings appear to be more inclined to respond rapidly to SRIs, enabling intermittent treatment, than are, for example, the somatic symptoms...
  25. ncbi [What our patients want and need to know about generalized anxiety disorder]
    Christer Allgulander
    Instituto Karolinska, Departamento de Neurociência Clínica, Divisão de Psiquiatria, Estocolmo, Suecia
    Rev Bras Psiquiatr 29:172-6. 2007
    ....
  26. ncbi Absence of the Arg441His polymorphism in the tryptophan hydroxylase 2 gene in adults with anxiety disorders and depression
    Susanne Henningsson
    Am J Med Genet B Neuropsychiatr Genet 144:816-7. 2007
  27. ncbi Genetics and personality traits in patients with social anxiety disorder: a case-control study in South Africa
    Christine Lochner
    MRC Unit on Anxiety and Stress Disorders, Department of Psychiatry, University of Stellenbosch, South Africa
    Eur Neuropsychopharmacol 17:321-7. 2007
    ..to compare differences in temperament dimensions between carriers of different (dominant vs. recessive) alleles for selected polymorphisms in SAD patients...
  28. ncbi [High societal costs of brain diseases. Extremely small resources allocated to research on prevention and treatment]
    Patrik Sobocki

    Lakartidningen 104:1590-4. 2007